221 related articles for article (PubMed ID: 19473225)
1. Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.
Loven D; Levavi H; Sabach G; Zart R; Andras M; Fishman A; Karmon Y; Levi T; Dabby R; Gadoth N
Eur J Cancer Care (Engl); 2009 Jan; 18(1):78-83. PubMed ID: 19473225
[TBL] [Abstract][Full Text] [Related]
2. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation.
Argyriou AA; Chroni E; Koutras A; Iconomou G; Papapetropoulos S; Polychronopoulos P; Kalofonos HP
J Pain Symptom Manage; 2006 Sep; 32(3):237-44. PubMed ID: 16939848
[TBL] [Abstract][Full Text] [Related]
3. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial.
Argyriou AA; Chroni E; Koutras A; Ellul J; Papapetropoulos S; Katsoulas G; Iconomou G; Kalofonos HP
Neurology; 2005 Jan; 64(1):26-31. PubMed ID: 15642899
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.
Davis ID; Kiers L; MacGregor L; Quinn M; Arezzo J; Green M; Rosenthal M; Chia M; Michael M; Bartley P; Harrison L; Daly M
Clin Cancer Res; 2005 Mar; 11(5):1890-8. PubMed ID: 15756015
[TBL] [Abstract][Full Text] [Related]
5. Reduction of paclitaxel-induced peripheral neuropathy with glutamine.
Vahdat L; Papadopoulos K; Lange D; Leuin S; Kaufman E; Donovan D; Frederick D; Bagiella E; Tiersten A; Nichols G; Garrett T; Savage D; Antman K; Hesdorffer CS; Balmaceda C
Clin Cancer Res; 2001 May; 7(5):1192-7. PubMed ID: 11350883
[TBL] [Abstract][Full Text] [Related]
6. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias.
Jacobson SD; Loprinzi CL; Sloan JA; Wilke JL; Novotny PJ; Okuno SH; Jatoi A; Moynihan TJ
J Support Oncol; 2003; 1(4):274-8. PubMed ID: 15334869
[TBL] [Abstract][Full Text] [Related]
7. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes.
Mielke S; Sparreboom A; Mross K
Eur J Cancer; 2006 Jan; 42(1):24-30. PubMed ID: 16293411
[TBL] [Abstract][Full Text] [Related]
8. Tracing the incidence of paclitaxel-induced peripheral neuropathy.
Argyriou AA
Eur J Cancer Care (Engl); 2009 Sep; 18(5):522-3. PubMed ID: 19674075
[No Abstract] [Full Text] [Related]
9. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
[TBL] [Abstract][Full Text] [Related]
10. Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery.
Storey DJ; Colvin LA; Mackean MJ; Mitchell R; Fleetwood-Walker SM; Fallon MT
J Pain Symptom Manage; 2010 Jun; 39(6):e2-4. PubMed ID: 20538177
[No Abstract] [Full Text] [Related]
11. Reversible paclitaxel-induced vocal cord paralysis with later recall with vinorelbine.
Choi BS; Robins HI
Cancer Chemother Pharmacol; 2008 Feb; 61(2):345-6. PubMed ID: 18026678
[TBL] [Abstract][Full Text] [Related]
12. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
Amara S
Ann Pharmacother; 2008 Oct; 42(10):1481-5. PubMed ID: 18698011
[TBL] [Abstract][Full Text] [Related]
13. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K
Clin Cancer Res; 2005 Jul; 11(13):4843-50. PubMed ID: 16000582
[TBL] [Abstract][Full Text] [Related]
14. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer.
van der Hoop RG; Vecht CJ; van der Burg ME; Elderson A; Boogerd W; Heimans JJ; Vries EP; van Houwelingen JC; Jennekens FG; Gispen WH
N Engl J Med; 1990 Jan; 322(2):89-94. PubMed ID: 2152972
[TBL] [Abstract][Full Text] [Related]
15. Glutamate ameliorates experimental vincristine neuropathy.
Boyle FM; Wheeler HR; Shenfield GM
J Pharmacol Exp Ther; 1996 Oct; 279(1):410-5. PubMed ID: 8859020
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of duloxetine for Paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients.
Otake A; Yoshino K; Ueda Y; Sawada K; Mabuchi S; Kimura T; Kobayashi E; Isobe A; Egawa-Takata T; Matsuzaki S; Fujita M; Kimura T
Anticancer Res; 2015 Jan; 35(1):359-63. PubMed ID: 25550572
[TBL] [Abstract][Full Text] [Related]
17. Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel.
Jamieson SM; Liu JJ; Connor B; Dragunow M; McKeage MJ
Neurotoxicology; 2007 Nov; 28(6):1092-8. PubMed ID: 17686523
[TBL] [Abstract][Full Text] [Related]
18. Ganglioside GM1 (porcine) ameliorates paclitaxel-induced neuropathy in rats.
Chentanez V; Thanomsridejchai N; Duangmardphon N; Agthong S; Kaewsema A; Huanmanop T; Maneesri S
J Med Assoc Thai; 2009 Jan; 92(1):50-7. PubMed ID: 19260244
[TBL] [Abstract][Full Text] [Related]
19. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial.
Ghoreishi Z; Esfahani A; Djazayeri A; Djalali M; Golestan B; Ayromlou H; Hashemzade S; Asghari Jafarabadi M; Montazeri V; Keshavarz SA; Darabi M
BMC Cancer; 2012 Aug; 12():355. PubMed ID: 22894640
[TBL] [Abstract][Full Text] [Related]
20. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study.
Stubblefield MD; Vahdat LT; Balmaceda CM; Troxel AB; Hesdorffer CS; Gooch CL
Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):271-6. PubMed ID: 15997923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
